- Indication of PCSK9 inhibitors in the expert view of the CSAT2016 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Monoklonal PCSK9 antibodies in the treatment of dyslipidemias2014 | First Faculty of Medicine
- Biological therapy in cardiology - New studies with antibodies directed against PCSK92015 | First Faculty of Medicine
- The study ODYSSEY CHOICE I with alirocumab: more data on PCSK9 inhibition2017 | First Faculty of Medicine
- PCSK9 inhibitors in light of recent data2016 | First Faculty of Medicine
- PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated? Czech atherosclerosis society statement2016 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- PCSK9 Molecule: Characteristics and Clinical Importance2019 | Third Faculty of Medicine
- Evolocumab - antibody against PCSK9 with a profound lipid-lowering effect2015 | First Faculty of Medicine
- Ezetimibe and combination of lipid lowering medications: what is their role in the era of PCSK9 inhibitors?2017 | First Faculty of Medicine
- The study ODYSSEY FH I and II with alirokumabem: other pieces in the mosaic of influences inhibition of PCSK92015 | First Faculty of Medicine
- Perspectives of further reduction in cholesterol by means of PCSK9 blockade2013 | Faculty of Medicine in Hradec Králové
- Inhibitors PCSK9 - experience after two years of practice in the Czech Republic2017 | Faculty of Medicine in Hradec Králové
- Léčba PCSK9 inhibitory v praxPublication without faculty affiliation
- New possibilities of dyslipidemiaa therapy in patients with familial hypercholesterolemia in secondary prevention - change in reimbursement for PCSK9 inhibitors2021 | First Faculty of Medicine
- The treatment of hypercholesterolemia by PCSK9 inhibitors2014 | Faculty of Medicine in Hradec Králové
- Aktuality ze světa inhibice PCSK92019 | First Faculty of Medicine
- Turn in hypercholesterolemia treatment - PCSK9 inhibitors. What we know about the alirocumab (product Praluent(R)) yet?2016 | First Faculty of Medicine
- Terapie inhibitory PCSK9 u pacientů se statinovou intolerancí2019 | First Faculty of Medicine
- Regulation of intracellular metabolism of LDL-cholesterol: the importance of inhibition of PCSK92014 | Faculty of Medicine in Hradec Králové
- Evolocumab - a new era in the treatment of dyslipidemia2015 | First Faculty of Medicine
- Will it be more effective in cardiovascular events than the monoclonal antibodies against PCSK9?2018 | Faculty of Medicine in Hradec Králové
- Inhibitor of PCSK9 protein - alirocumab in clinical trials, ODYSSEY program2018 | First Faculty of Medicine
- PCSK9-9 inhibition in cardiology2016 | Faculty of Medicine in Hradec Králové
- PCSK9 inhibitory: milník v léčbě dyslipidemií2016 | First Faculty of Medicine
- Monoclonal antibodies in the treatment of dyslipidemia and cardiovascular risk lowering2016 | First Faculty of Medicine
- Co přinesla studie FOURIER? Důkazy pro inhibitory PCSK9, nebo "jen" potvrdila LDL hypotézu?2017 | First Faculty of Medicine
- Slibný perorální inhibitor PCSK9 ve vývoji2023 | First Faculty of Medicine
- First impressions of the ODYSSEY Outcomes trial2018 | First Faculty of Medicine
- News in cardiovascular prevention: from guidelines to novel treatment options2015 | First Faculty of Medicine
- Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights from the FOURIER Trial2019 | First Faculty of Medicine